NRAS is a member of the RAS family of oncogenes and activating mutations of NRAS have been reported in a wide variety of tumors including occasional cases of cholangiocarcinomas.
Voss, Jesse S., et al. "Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions." Human pathology 44.7 (2013): 1216-1222.
Deshpande, Vikram, et al. "Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma." BMC cancer 11.1 (2011): 60.
Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015 Oct;99(2):240-4. doi:0.1016/j.yexmp.2015.07.005. Epub 2015 Jul 17. PubMed PMID: 26189129; PubMed Central PMCID: PMC4591249.
Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014 Nov;21(12):3827-34. doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3. PubMed PMID: 24889489; PubMed Central PMCID: PMC4324507.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.